$47.01
-0.50[-1.05%]
Last update: 2:35PM Get Real Time Here
Apellis Pharmaceuticals
(NASDAQ:APLS)Apellis Pharmaceuticals Stock (NASDAQ:APLS), Analyst Ratings, Price Targets, Predictions
Apellis Pharmaceuticals Inc has a consensus price target of $77.67, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, HC Wainwright & Co., and Needham on April 17, 2024, April 15, 2024, and April 9, 2024. With an average price target of $78 between Wedbush, HC Wainwright & Co., and Needham, there's an implied 65.92% upside for Apellis Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
HC Wainwright & Co.
Needham
Mizuho
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Apellis Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/17/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 21.25% | Wedbush | Laura Chico | $67 → $57 | Maintains | Neutral | Get Alert |
| 04/15/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 95.7% | HC Wainwright & Co. | Douglas Tsao | → $92 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 80.81% | Needham | Joseph Stringer | → $85 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 27.63% | Mizuho | Graig Suvannavejh | $60 → $60 | Maintains | Neutral | Get Alert |
| 03/06/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 68.05% | JP Morgan | Anupam Rama | $78 → $79 | Maintains | Overweight | Get Alert |
| 03/04/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 89.32% | UBS | Eliana Merle | $87 → $89 | Maintains | Buy | Get Alert |
| 02/28/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 95.7% | HC Wainwright & Co. | Douglas Tsao | → $92 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 42.52% | Wedbush | Laura Chico | $60 → $67 | Maintains | Neutral | Get Alert |
| 02/16/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 27.63% | Mizuho | Graig Suvannavejh | $49 → $60 | Maintains | Neutral | Get Alert |
| 02/06/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 72.3% | Baird | Colleen Kusy | → $81 | Reiterates | Outperform → Outperform | Get Alert |
| 02/05/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 70.18% | Jefferies | Akash Tewari | $68 → $80 | Upgrade | Hold → Buy | Get Alert |
| 01/30/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 68.05% | Oppenheimer | Justin Kim | $75 → $79 | Maintains | Outperform | Get Alert |
| 01/24/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 59.54% | Needham | Joseph Stringer | $70 → $75 | Maintains | Buy | Get Alert |
| 01/17/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 72.3% | Baird | Colleen Kusy | $71 → $81 | Maintains | Outperform | Get Alert |
| 01/17/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 95.7% | HC Wainwright & Co. | Douglas Tsao | $82 → $92 | Maintains | Buy | Get Alert |
| 01/12/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 27.63% | Wedbush | Laura Chico | $39 → $60 | Maintains | Neutral | Get Alert |
| 01/11/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 125.48% | Raymond James | Steven Seedhouse | $67 → $106 | Maintains | Strong Buy | Get Alert |
| 01/09/2024 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 91.45% | Goldman Sachs | Salveen Richter | $65 → $90 | Maintains | Buy | Get Alert |
| 12/15/2023 | APLS | Buy Now | Apellis Pharmaceuticals | $47.01 | 42.52% | Citigroup | Yigal Nochomovitz | $70 → $67 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Apellis Pharmaceuticals (APLS)?
The latest price target for Apellis Pharmaceuticals (NASDAQ: APLS) was reported by Wedbush on April 17, 2024. The analyst firm set a price target for $57.00 expecting APLS to rise to within 12 months (a possible 21.25% upside). 70 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Apellis Pharmaceuticals (APLS)?
The latest analyst rating for Apellis Pharmaceuticals (NASDAQ: APLS) was provided by Wedbush, and Apellis Pharmaceuticals maintained their neutral rating.
When was the last upgrade for Apellis Pharmaceuticals (APLS)?
The last upgrade for Apellis Pharmaceuticals Inc happened on February 5, 2024 when Jefferies raised their price target to $80. Jefferies previously had a hold for Apellis Pharmaceuticals Inc.
When was the last downgrade for Apellis Pharmaceuticals (APLS)?
The last downgrade for Apellis Pharmaceuticals Inc happened on December 14, 2023 when Wells Fargo changed their price target from $67 to $54 for Apellis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Apellis Pharmaceuticals (APLS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apellis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apellis Pharmaceuticals was filed on April 17, 2024 so you should expect the next rating to be made available sometime around April 17, 2025.
Is the Analyst Rating Apellis Pharmaceuticals (APLS) correct?
While ratings are subjective and will change, the latest Apellis Pharmaceuticals (APLS) rating was a maintained with a price target of $67.00 to $57.00. The current price Apellis Pharmaceuticals (APLS) is trading at is $47.01, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.